Latest News

None

Brentuximab Vedotin May Improve Overall Survival in Patients with Hodgkin Lymphoma

A study led by researchers from Mayo Clinic Comprehensive Cancer Center has found that the addition of brentuximab vedotin to standard chemotherapy treatment improves overall survival in patients with Hodgkin Lymphoma, when compared to the current standard of chemotherapy alone. Results of the research were presented by Stephen Ansell, M.D., Ph.D., at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO) in Chicago and were published today in the New England Journal of Medicine.

Language Pod researchers engage COSI visitors in real-life research

Throughout the year, researchers working at The Ohio State University’s Language Pod are engaging visitors to COSI in downtown Columbus in the study of how people process languages.

A partnership between Ohio State and COSI, the Language Pod (formally known as the Language Sciences Research Lab) marked its 10th anniversary with a June 2 celebration at the science museum. The COSI research pods, located on the museum’s second floor, are a part of a larger COSI exhibit on the life sciences. The pods are glass-enclosed research spaces where museum visitors can observe scientific research taking place in real time.